Patents and Licences

Discovery:  Optimization of the use of CAMPATH-1H therapy in the induction tolerance: exploiting lymphocyte depletion by using

anti-IL7R antibodies to favour regulation.

Inventor(s): H. WALDMANN, U. Oxford

IP Protection Measures:  IP protection request is ongoing

Discovery:  Method of determining an individual’s transplantation tolerance by determining the level of a number of biomarkers. Designing a kit comprising reagents for detecting the levels of the biomarkers and to a sensor for detecting the expression levels of a plurality of genes to determine an individual’s transplantation tolerance.

Inventor(s):  King’s College London, Miltenyi Biotec GmbH and

Charité - Universitätsmedizin Berlin

IP Protection Measures:   Patent application n° GB 1007454.0 filled on the

04/05/210 at the UK patent office

Commercial / Industrial Exploitation:   No licensees have currently been identified

Discovery:  Identification of transcriptional biomarkers capable of predicting the outcome of immunosuppression withdrawal in stable liver transplant recipients.

Inventor(s):   A. SANCHEZ FUEYO, IDIBAPS

IP Protection Measures:  Applications filed n° WO2008081039 and WO2010000848

Commercial / Industrial Exploitation:   1 licensing agreement has been settled with TcLAND Expression SA for the commercial exploitation of the result

IP Protection Measures:  TSDR analysis as such is protected by a patent of Prof. Hamann (CHARITE) and Epiontis GmbH. It has been licensed to CHARITE for developing qPCR (quantitative TSDR analysis) in human samples

Discovery:   Gene expression profiling by qRT-PCR: Toag-1 is a marker for quantifying the summative activation/silence balance of adaptive immunity in general, and better understanding the regulatory mechanisms behind

Inventor(s):   B. SAWITZKI, H.-D. VOLK, Charité - Universitätsmedizin Berlin M. LEHMANN, K. WOOD, U. Oxford

IP Protection Measures:  Toag-1 and aMann expression analysis was already protected by a patent: “Immune marker fur die Diagnose und Therapie von transplantation”.   Patent application filed n° WO 2004/018504 A2, 04.03.2004-

Commercial / Industrial Exploitation:  The commercial exploitation of the result has been licensed to Miltenyi Biotec GmbH

Discovery:  Improved minimizing immunosuppression by targeting allospecific memory (campath/infliximab)

Inventor(s):   IKEM, Charité - Universitätsmedizin Berlin

IP Protection Measures:  IP protection request is ongoing.

Discovery:  Molecular pattern of tolerance

Inventor(s):   King’s College London, Miltenyi Biotec GmbH and Charité - Universitätsmedizin Berlin

IP Protection Measures:  Patent application filed

Discovery:  ELISPOT analysis for detecting cellular sensitized transplant patients

Inventor(s):   REINKE, VOLK, Charité - Universitätsmedizin GRINYO, IDIBELL

Commercial / Industrial Exploitation:   Collaboration initiated with Autoimmun Diagnostika GmbH (AID). ELISPOT assay will be commercialised by AID.

Discovery:  B-Cell ELISPOT for detecting alloreactive memory B-cells

Inventor(s):  Charité - Universitätsmedizin Leiden University Medical Centre

IP Protection Measures:  IP protection opportunity is currently under evaluation

Discovery:  Bedside test for urinary IP-10

Inventor(s):   Charité - Universitätsmedizin

Commercial / Industrial Exploitation:   A collaboration with Miltenyi Biotec GmbH has been settled for the co-development of a commercial test